Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

29 Mar 2019
The benefit of immediate compared to deferred ART on CD4+ Cell count recovery in early HIV infection
Sharma S, Schlusser KE, Torre P, Tambussi G, Draenert R, Pinto AN, Metcalf JA, Neaton JD, Laeyendecker O; INSIGHT START Study Group.
AIDS, 2019: 10.1097/QAD.0000000000002219
12 Feb 2019
Cross-sectional HIV Incidence Estimation Accounting for Heterogeneity Across Communities
Xu Y, Laeyendecker O, Wang R
Biometrics, 2019: 10.1111/biom.13046
1 Dec 2018
Cross-Sectional HIV Incidence Estimation with Missing Biomarkers
Morrison D, Laeyendecker O, Konikoff J, Brookmeyer R
Stat Commun Infect Dis, 2018: 10(1): pii: 20170, 10.1515/scid-2017-0003
Segmented polynomials for incidence rate estimation from prevalence data.
Mahiané SG, Laeyendecker O.
Stat Med. , 2017: 36(2): 334-344, 10.1002/sim.7130
Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence
Schlusser KE, Konikoff J, Kirkpatrick AR, Morrison C, Chipato T, Chen PL, Munjoma M, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2017: doi:10.1089/AID.2016.0245.
Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population.
Rose R, Lamers SL, Massaccesi G, Osburn W, Ray SC, Thomas DL, Cox AL, Laeyendecker O.
Infect Genet Evol, 2017: 58: 77-82, 10.1016/j.meegid.2017.12.015
20 Oct 2016
Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources.
Mayaphi SH, Martin DJ, Quinn TC, Laeyendecker O, Olorunju SA, Tintinger GR, Stoltz AC.
PLoS One, 2016: 11(10): e0164943, 10.1371/journal.pone.0164943
Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study.
Solomon SS, Mehta SH, McFall AM, Srikrishnan AK, Saravanan S, Laeyendecker O, Balakrishnan P, Celentano DD, Solomon S, Lucas GM.
Lancet HIV, 2016: 3(4): e183-90., 10.1016/S2352-3018(16)00019-9

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Images

Contact

Tel: 410-955-3551

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Justin Lessler
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6545
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2021 Infectious Disease Dynamics
Website by Manta Ray Media